Trial · NCT07280377
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
NCT07280377, Phase 1, Phase 2, Active not recruiting, Oncolytics Biotech
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab. Trials, record NCT07280377. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07280377
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
- NCT number
- NCT07280377
- Status
- Active not recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 122 participants, estimated
- Lead sponsor
- Oncolytics Biotech
- Conditions
- Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma
- Interventions
- Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel, Trifluridine Tipiracil, mFOLFIRINOX Treatment Regimen
- First posted
- 2025-12-12
- Last updated
- 2026-05-19
- Other registries' IDs
- eudract:2020-003996-16
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate (ORR) for Cohort 1, 2, 4, and 5 | At week 16 (within each cohort) | Proportion of patients with complete response \[CR\], partial response \[PR\] assessed by the investigators and/or central reader according to RECIST v1.1 |
| Primary | Disease Control Rate (DCR) - Cohort 3 | at week 16 | DCR (complete response \[CR\], partial response \[PR\], and stable disease \[SD\]) assessed by the investigators according to RECIST v 1.1. |
| Primary | Overall Survival (OS) - Cohort 5 | Cohort 5: From the date of randomization through long term follow up at 2 years | OS is defined as the time from date of first treatment to death from any cause |
| Secondary | Progression Free Survival (PFS) | From initiation of treatment to objective progression or death from any cause, whichever occurs first, up to two years | Time from the first dose date of study treatment to the date of investigator-determined objective progression (according to RECIST 1.1) or death from any cause, whichever occurs first. |
| Secondary | Duration of Response (DOR) | From initiation of treatment to disease progression or death from any cause, whichever occurs first, up to two years | Time from documentation of the first CR or PR to the time of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death. |
| Secondary | Disease Control Rate (DCR) | From initiation of treatment to disease progression or death from any cause, whichever occurs first, up to two years | Overall DCR, defined as the number of patients with a best overall response of CR, PR, or SD according to RECIST v. 1.1. |
| Secondary | Overall Response Rate (ORR) - Cohort 1-4 | From initiation of treatment to disease progression or death from any cause, whichever occurs first, up to two years | ORR, defined as the percentage of patients with a best overall response of complete response \[CR\] or partial response \[PR\] according to RECIST v 1.1, and confirmed ORR, defined as the percentage of patients with a CR or PR at two or more consecutive evaluation timepoints. |
| Secondary | Overall Survival (OS) - Cohort 1-4 | From the date of randomization through long term follow up at 3 years | OS defined as the time from date of first treatment to death from any cause |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07280377
GET https://conductscience.org/api/trials/v1/NCT07280377/registered